 BriaCell Therapeutics Corp NASDAQ: BCTX shares are trading higher on Wednesday after the company announced it is expanding its breast cancer platform into prostate, melanoma and lung cancers. The expansion includes Bria-Pros for prostate cancer, Bria-Mel for melanoma and Bria-Lung for lung cancer and the company anticipates commencing clinical trials for these therapies in 2022. 